



Cálculo de riesgo cardiovascular³



Riesgo a 10 años de ECV mortal en poblaciones con bajo riesgo de ECV

Referencias: 1. Koenig W et al. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk \geq 5% or Framingham risk $>$ 20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2011;32(1):75-83. 2. Según nomenclator noviembre 2017. 3. Piepoli MF, Hoes AW, Agewall S, et al. Eur Heart J 2016;37:2315-8. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).



ALTER MÈDICA
Garantía de Marca

ARROX

Rosuvastatina

En el control del colesterol los números cuentan

historias



%

... *menos* de riesgo de sufrir un evento cardiovascular mayor¹

ARROX/RIESGO ENERO2018



ALTER MÈDICA
Garantía de Marca